Search Within

Joachim Yahalom

  1. "Blood"
Formats
  1. Meeting Abstract (80)
  2. Journal Article (15)
  3. Guidelines (1)
Groups
  1. Radiation Oncology, Department of (96)
  2. Survivorship Research (96)
  3. Department of Medicine (81)
  4. Hematologic Malignancies, Division of (80)
  5. Center for Hematologic Malignancies (77)
  6. Lymphoma (65)

More Groups

People
  1. Andrew Zelenetz (49)
  2. Craig Moskowitz (37)
  3. Ariela Noy (31)
  4. David Straus (31)
  5. Brandon Imber (29)
  6. Maria Palomba (25)

More People

Years
  1. 2024 (4)
  2. 2023 (12)
  3. 2022 (9)
  4. 2021 (8)
  5. 2020 (4)
  6. 2019 (9)

More Years

Publications
  1. Blood (96)
Publishers
  1. American Society of Hematology (96)

Results (96)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CNS radiotherapy as bridging prior to CAR T-cell therapy for non-Hodgkin B-cell lymphoma
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S. M.; Hubbeling, H.; Tringale, K.; Shah, G. L.; Tomas, A. A.; Shouval, R.; Hajj, C.; Fregonese, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A. D.; Salles, G.; Yahalom, J.; Imber, B. S.
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for relapsed/refractory secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Salles, G.; Grommes, C.; Scordo, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Primary hepatic lymphoma: Role of low-dose radiotherapy at a single institution with genetic characterization and paired literature review
    Meeting Abstract

    Ma, J.; Daou, R.; Eid, J. B.; Lee, J.; Fregonese, B.; El-Khoury, J.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K. R.; Lebow, E. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas
    Meeting Abstract

    Fregonese, B.; Dreyfuss, A.; Lee, J.; Imber, B. S.; Yahalom, J.; Hajj, C.
    Blood (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of splenic irradiation for non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H.; Imber, B. S.; Wijetunga, N. A.; Tringale, K. R.; Hajj, C.; Yahalom, J.
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save